There are challenges that go beyond technology to embrace the deepest value of care.
For Biomed Device, supporting the COL20 Protocol is not merely about participating in a study; it is about being part of a courageous journey toward new therapeutic frontiers.
COL20 is an initiative of Italian excellence: a non-profit monocentric study promoted by the Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome.
The soul of this project lies in a rigorous clinical path exploring the regenerative potential of CB-PRP (Cord Blood Platelet-Rich Plasma) to combat dry-AMD, a condition affecting millions of lives.
The essence of this activity is defined by absolute precision: the intravitreal administration of micro- volumes of platelet-rich plasma, derived from a pool of donated cord blood units and standardized through meticulous processes to ensure consistency and reliability at every stage.
The results achieved so far speak to a tireless dedication to safety.
With 122 injections performed, the protocol has demonstrated a perfect safety profile, with no adverse events or inflammatory reactions recorded.
This scientific milestone gives us the strength to look ahead with determination, supporting the clinicians committed to slowing disease progression.
For us, standing alongside such a prestigious clinical center is a way to substantiate the excellence of the processes and the safety of the patient.
COL20 is not a final destination, but the promise of a commitment that continues, day after day, in the name of regenerative medicine.